$1.25 Million in Sales Expected for Aclaris Therapeutics Inc (NASDAQ:ACRS) This Quarter

Brokerages predict that Aclaris Therapeutics Inc (NASDAQ:ACRS) will announce $1.25 million in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Aclaris Therapeutics’ earnings, with the lowest sales estimate coming in at $1.13 million and the highest estimate coming in at $1.40 million. Aclaris Therapeutics posted sales of $5.87 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 78.7%. The company is scheduled to report its next quarterly earnings results on Thursday, August 13th.

On average, analysts expect that Aclaris Therapeutics will report full-year sales of $5.15 million for the current fiscal year, with estimates ranging from $4.72 million to $5.60 million. For the next financial year, analysts forecast that the company will post sales of $5.45 million, with estimates ranging from $4.50 million to $6.80 million. Zacks’ sales averages are a mean average based on a survey of analysts that cover Aclaris Therapeutics.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter. Aclaris Therapeutics had a negative return on equity of 99.67% and a negative net margin of 1,490.64%. The firm had revenue of $1.41 million during the quarter, compared to analysts’ expectations of $1.27 million.

A number of brokerages recently weighed in on ACRS. Zacks Investment Research downgraded shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday. ValuEngine raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, March 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $3.13.

Shares of Aclaris Therapeutics stock traded down $0.02 on Monday, reaching $1.72. The stock had a trading volume of 68,967 shares, compared to its average volume of 1,047,061. The business’s 50 day moving average is $1.47 and its two-hundred day moving average is $1.40. The company has a market cap of $74.10 million, a P/E ratio of -0.52 and a beta of 1.17. The company has a current ratio of 4.01, a quick ratio of 4.01 and a debt-to-equity ratio of 0.18. Aclaris Therapeutics has a 1 year low of $0.70 and a 1 year high of $2.45.

Hedge funds have recently bought and sold shares of the business. Marshall Wace LLP purchased a new position in shares of Aclaris Therapeutics during the first quarter worth approximately $103,000. Oxford Asset Management LLP purchased a new position in shares of Aclaris Therapeutics during the fourth quarter worth approximately $52,000. UBS Group AG raised its stake in shares of Aclaris Therapeutics by 317.4% during the fourth quarter. UBS Group AG now owns 37,806 shares of the biotechnology company’s stock worth $71,000 after acquiring an additional 28,749 shares in the last quarter. Wells Fargo & Company MN raised its stake in shares of Aclaris Therapeutics by 100.3% during the first quarter. Wells Fargo & Company MN now owns 52,350 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 26,213 shares in the last quarter. Finally, HighTower Advisors LLC raised its stake in shares of Aclaris Therapeutics by 16.8% during the first quarter. HighTower Advisors LLC now owns 69,635 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 10,000 shares in the last quarter. 81.27% of the stock is currently owned by hedge funds and other institutional investors.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.

Featured Article: What is a death cross?

Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.